[go: up one dir, main page]

FR3011009B1 - Signature bacterienne de la dermatite atopique et son utilisation dans la prevention et/ou le traitement de cette pathologie - Google Patents

Signature bacterienne de la dermatite atopique et son utilisation dans la prevention et/ou le traitement de cette pathologie

Info

Publication number
FR3011009B1
FR3011009B1 FR1359249A FR1359249A FR3011009B1 FR 3011009 B1 FR3011009 B1 FR 3011009B1 FR 1359249 A FR1359249 A FR 1359249A FR 1359249 A FR1359249 A FR 1359249A FR 3011009 B1 FR3011009 B1 FR 3011009B1
Authority
FR
France
Prior art keywords
pathology
prevention
treatment
atopic dermatitis
bacterial signature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1359249A
Other languages
English (en)
Other versions
FR3011009A1 (fr
Inventor
Richard Martin
Sophie Seite
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Priority to FR1359249A priority Critical patent/FR3011009B1/fr
Priority to US15/024,683 priority patent/US20160215326A1/en
Priority to PCT/EP2014/070574 priority patent/WO2015044315A1/fr
Priority to EP14781106.1A priority patent/EP3049533B1/fr
Publication of FR3011009A1 publication Critical patent/FR3011009A1/fr
Application granted granted Critical
Publication of FR3011009B1 publication Critical patent/FR3011009B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/20Dermatological disorders
    • G01N2800/202Dermatitis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1359249A 2013-09-25 2013-09-25 Signature bacterienne de la dermatite atopique et son utilisation dans la prevention et/ou le traitement de cette pathologie Expired - Fee Related FR3011009B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR1359249A FR3011009B1 (fr) 2013-09-25 2013-09-25 Signature bacterienne de la dermatite atopique et son utilisation dans la prevention et/ou le traitement de cette pathologie
US15/024,683 US20160215326A1 (en) 2013-09-25 2014-09-25 Bacterial signature of atopic dermatitis and use thereof in the prevention and/or treatment of this pathology
PCT/EP2014/070574 WO2015044315A1 (fr) 2013-09-25 2014-09-25 Signature bactérienne de dermatite atopique et son utilisation dans la prévention et/ou le traitement de cette pathologie
EP14781106.1A EP3049533B1 (fr) 2013-09-25 2014-09-25 Signature bactérienne de la dermatite atopique et son utilisation dans la prévention et/ou le traitement de cette pathologie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1359249A FR3011009B1 (fr) 2013-09-25 2013-09-25 Signature bacterienne de la dermatite atopique et son utilisation dans la prevention et/ou le traitement de cette pathologie

Publications (2)

Publication Number Publication Date
FR3011009A1 FR3011009A1 (fr) 2015-03-27
FR3011009B1 true FR3011009B1 (fr) 2016-11-25

Family

ID=49713257

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1359249A Expired - Fee Related FR3011009B1 (fr) 2013-09-25 2013-09-25 Signature bacterienne de la dermatite atopique et son utilisation dans la prevention et/ou le traitement de cette pathologie

Country Status (4)

Country Link
US (1) US20160215326A1 (fr)
EP (1) EP3049533B1 (fr)
FR (1) FR3011009B1 (fr)
WO (1) WO2015044315A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140550A2 (fr) 2008-05-14 2009-11-19 Dermtech International Diagnostic de mélanome et de lentigo solaire par analyse d'acides nucléiques
JP2016528880A (ja) 2013-06-18 2016-09-23 プロダームアイキュー インコーポレイテッド 皮膚細菌叢の解析に基づくカスタマイズしたスキンケア製品及びパーソナルケア製品
CN107106429B (zh) 2014-11-10 2021-06-29 宝洁公司 具有两种有益相的个人护理组合物
MX376115B (es) 2014-11-10 2025-03-07 Procter & Gamble Composiciones para el cuidado personal con dos fases benéficas.
US10966916B2 (en) 2014-11-10 2021-04-06 The Procter And Gamble Company Personal care compositions
EP3346910A4 (fr) * 2015-09-09 2019-05-15 Ubiome Inc. Procédé et système pour diagnostics dérivés du microbiome et agents thérapeutiques contre l'eczéma
EP4345725A3 (fr) 2015-09-17 2024-06-19 Prodermiq, Inc. Prédiction de l'âge de la peau sur la base de l'analyse de la flore cutanée et des données de style de vie
CN110753966A (zh) 2017-03-10 2020-02-04 普罗皮肤检测股份有限公司 基于皮肤菌群分析的定制化护肤产品和个人护理产品
CN111212625B (zh) 2017-10-20 2023-05-23 宝洁公司 气溶胶泡沫洁肤剂
WO2019079405A1 (fr) 2017-10-20 2019-04-25 The Procter & Gamble Company Nettoyant moussant en aérosol pour la peau
CA3090785A1 (fr) 2018-02-14 2019-08-22 John Daniel Dobak Iii Nouveaux classificateurs de genes et leurs utilisations dans des cancers de la peau sans melanome
RU2692803C1 (ru) * 2018-10-08 2019-06-27 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ прогнозирования степени тяжести атопического дерматита у детей с сопутствующим дисбактериозом кишечника
CN113015904B (zh) 2018-11-29 2024-06-18 宝洁公司 用于筛选个人护理产品的方法
JP2020182435A (ja) * 2019-05-07 2020-11-12 学校法人慶應義塾 アトピー性皮膚炎の診断方法
FR3099770B1 (fr) * 2019-08-05 2023-01-13 Luxia Scient Methode d’analyse de la perte de diversite bacterienne du microbiome intestinal humain
CN115398198A (zh) 2020-03-24 2022-11-25 宝洁公司 用于测试皮肤样本的方法
EP4251773A4 (fr) * 2020-11-24 2024-10-30 Dermtech, Inc. Évaluation de la charge mutationnelle dans la peau
WO2022117442A1 (fr) 2020-12-01 2022-06-09 Evonik Operations Gmbh Culture mixte synthétique ressemblant à un microbiome cutané
FR3121936A1 (fr) * 2021-04-20 2022-10-21 Naos Institute Of Life Science Methode de criblage d’ingredients et de compositions topiques ecobiologiques, et son utilisation pour realiser un soin cosmetique de restauration du microbiote cutane

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008107275A (ja) * 2006-10-27 2008-05-08 Juntendo アレルギー性皮膚炎の診断法
US7919250B2 (en) * 2007-07-31 2011-04-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
US8906629B2 (en) * 2009-12-03 2014-12-09 Shiseido Company, Ltd. Method for screening ameliorants of dry skin caused by atopic dermatitis using bleomycin hydrolase activity as indicator
JP5520246B2 (ja) * 2011-02-25 2014-06-11 株式会社ファンケル アトピー性皮膚炎の検査方法
BR112015021755A2 (pt) * 2013-03-07 2017-07-18 Kane Biotech Inc composições antimicrobianas e antibiofilmes e métodos de aplicação das mesmas
WO2015095241A2 (fr) * 2013-12-16 2015-06-25 Seres Health, Inc. Compositions bactériennes et leurs méthodes d'utilisation pour traiter des troubles du système immunitaire

Also Published As

Publication number Publication date
US20160215326A1 (en) 2016-07-28
WO2015044315A1 (fr) 2015-04-02
EP3049533B1 (fr) 2018-12-26
FR3011009A1 (fr) 2015-03-27
EP3049533A1 (fr) 2016-08-03

Similar Documents

Publication Publication Date Title
FR3011009B1 (fr) Signature bacterienne de la dermatite atopique et son utilisation dans la prevention et/ou le traitement de cette pathologie
EP3720549A4 (fr) Systèmes et procédés de traitement de patient
EP3936095C0 (fr) Détection d'infections microbiennes dans des plaies
EP2931919A4 (fr) Procédés et systèmes pour le traitement de polynucléotides
SI3240554T1 (sl) Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
EP2978373A4 (fr) Système destiné à être utilisé dans le traitement de fractures vertébrales
EP2948188A4 (fr) Imagerie neuronale et traitement
EP3262407C0 (fr) Procédés et systèmes de traitement de cloisonnement
MA39960A (fr) Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer
EP2836270A4 (fr) Systèmes et procédés liés au traitement de la douleur dorsale
PT2953969T (pt) Anticorpos anti-il-17a e utilização dos mesmos no tratamento de distúrbios autoimunes e inflamatórios
EP2954065A4 (fr) Fractionnement et traitement d'analytes et d'autres espèces
EP3519833A4 (fr) Méthodes de pronostic et de traitement
EP3166688C0 (fr) Ligands de visualisation de tau et leurs utilisations dans le diagnostic et le traitement de tauopathies
HRP20180671T1 (hr) Pripravci za i postupci inhibiranja masp-1 i/ili masp-3 u liječenju paroksizmalne noćne hemoglobinurije
EP2962092A4 (fr) Procédés et systèmes de traitement micro-fluidique amélioré
IL252418B (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
EP2969010A4 (fr) Utilisation de levocetirizine et de montelukast dans le traitement des maladies auto-immunes
EP3365028A4 (fr) Détection et traitement de caries et de microcavités avec des nanoparticules
EP3576738A4 (fr) Utilisation de gaboxadol dans le traitement des acouphènes
EP3331984A4 (fr) Systèmes et procédés de traitement d'allogreffe rapides
EP2854910A4 (fr) Niveaux de céramide dans le traitement et la prévention d'infections
EP3259600C0 (fr) Dosage diagnostique et traitement de la pré-éclampsie
FR2999428B1 (fr) Chitine ou derives de chitine pour utilisation dans la prevention et/ou le traitement de parasitoses
MA42915A (fr) Pyridines et leur utilisation dans le traitement du cancer

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

ST Notification of lapse

Effective date: 20210506